α1A-AR CRISPR/Cas9 KO Plasmid (h): sc-401726
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- α1A-AR CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the α1A-AR genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: α1A-AR Antibody (4D8): sc-100291
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
α1A-AR CRISPR/Cas9 KO Plasmid (h) | sc-401726 | 20 µg | $397.00 |
Overview
ADRA1A encodes the human α1A-adrenergic receptor (α1A-AR), a G protein–coupled receptor that preferentially couples to Gq/11 to activate phospholipase C, elevate intracellular Ca2+, and stimulate PKC-dependent signaling. α1A-AR regulates smooth muscle contraction, vascular tone, and neurotransmission, and can engage downstream MAPK/ERK pathways that influence cellular proliferation and transcriptional programs. Receptor activity contributes to adrenergic control of cardiovascular and genitourinary physiology and modulates stress-responsive signaling networks in multiple tissues. Dysregulated adrenergic signaling and altered ADRA1A expression have been investigated in contexts including hypertension, lower urinary tract function, and tumor microenvironment signaling, providing a mechanistic entry point for pathway-focused research.
α1A-AR CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ADRA1A gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ADRA1A together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ADRA1A open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish α1A-AR protein expression.
This CRISPR knockout system enables efficient generation of ADRA1A-deficient cell models for investigation of α1A-AR signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ADRA1A exon(s) critical for α1A-AR function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ADRA1A genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by α1A-AR CRISPR/Cas9 KO Plasmid (h) and α1A-AR CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ADRA1A locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by α1A-AR HDR Plasmid (h) and α1A-AR HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ADRA1A homology arms to support homology-directed repair at defined ADRA1A target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.